Depleted myocardial coenzyme Q10 in cavalier king charles spaniels with congestive heart failure due to myxomatous mitral valve disease
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Depleted myocardial coenzyme Q10 in cavalier king charles spaniels with congestive heart failure due to myxomatous mitral valve disease. / Christiansen, Liselotte B.; Reimann, Maria J.; Schou-Pedersen, Anne Marie V.; Larsen, Steen; Lykkesfeldt, Jens; Olsen, Lisbeth H.
In: Antioxidants, Vol. 10, No. 2, 161, 2021, p. 1-13.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Depleted myocardial coenzyme Q10 in cavalier king charles spaniels with congestive heart failure due to myxomatous mitral valve disease
AU - Christiansen, Liselotte B.
AU - Reimann, Maria J.
AU - Schou-Pedersen, Anne Marie V.
AU - Larsen, Steen
AU - Lykkesfeldt, Jens
AU - Olsen, Lisbeth H.
PY - 2021
Y1 - 2021
N2 - Congestive heart failure (CHF) has been associated with depleted myocardial coenzyme Q10 (Q10) concentrations in human patients. The aim of this study was to investigate associations between myocardial Q10 concentrations and myxomatous mitral valve disease (MMVD) severity in dogs. Furthermore, citrate synthase (CS) activity was analysed to determine if a reduction in myocardial Q10 was associated with mitochondrial depletion in the myocardium. Thirty Cavalier King Charles spaniels (CKCS) in MMVD stages B1 (n = 11), B2 (n = 5) and C (n = 14) according to the American College of Veterinary Internal Medicine (ACVIM) guidelines and 10 control (CON) dogs of other breeds were included. Myocardial Q10 concentration was analysed in left ventricular tissue samples using HPLC-ECD. CKCS with congestive heart failure (CHF; group C) had significantly reduced Q10 concentrations (median, 1.54 µg/mg; IQR, 1.36–1.94), compared to B1 (2.76 µg/mg; 2.10–4.81, p < 0.0018), B2 (3.85 µg/mg; 3.13–4.46, p < 0.0054) and CON dogs (2.8 µg/mg; 1.64–4.88, p < 0.0089). CS activity was comparable between disease groups. In conclusion, dogs with CHF due to MMVD had reduced myocardial Q10 concentrations. Studies evaluating antioxidant defense mechanisms as a therapeutic target for treatment of CHF in dogs are warranted.
AB - Congestive heart failure (CHF) has been associated with depleted myocardial coenzyme Q10 (Q10) concentrations in human patients. The aim of this study was to investigate associations between myocardial Q10 concentrations and myxomatous mitral valve disease (MMVD) severity in dogs. Furthermore, citrate synthase (CS) activity was analysed to determine if a reduction in myocardial Q10 was associated with mitochondrial depletion in the myocardium. Thirty Cavalier King Charles spaniels (CKCS) in MMVD stages B1 (n = 11), B2 (n = 5) and C (n = 14) according to the American College of Veterinary Internal Medicine (ACVIM) guidelines and 10 control (CON) dogs of other breeds were included. Myocardial Q10 concentration was analysed in left ventricular tissue samples using HPLC-ECD. CKCS with congestive heart failure (CHF; group C) had significantly reduced Q10 concentrations (median, 1.54 µg/mg; IQR, 1.36–1.94), compared to B1 (2.76 µg/mg; 2.10–4.81, p < 0.0018), B2 (3.85 µg/mg; 3.13–4.46, p < 0.0054) and CON dogs (2.8 µg/mg; 1.64–4.88, p < 0.0089). CS activity was comparable between disease groups. In conclusion, dogs with CHF due to MMVD had reduced myocardial Q10 concentrations. Studies evaluating antioxidant defense mechanisms as a therapeutic target for treatment of CHF in dogs are warranted.
KW - Antioxidant
KW - Degenerative mitral valve disease
KW - Dog
KW - Heart
KW - Mitochondria
U2 - 10.3390/antiox10020161
DO - 10.3390/antiox10020161
M3 - Journal article
C2 - 33499156
AN - SCOPUS:85099715316
VL - 10
SP - 1
EP - 13
JO - Antioxidants
JF - Antioxidants
SN - 2076-3921
IS - 2
M1 - 161
ER -
ID: 256069373